GlobeNewswire Inc | Sep 30, 2020 07:00AM EDT

September 30, 2020

GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:

-- H.C. Wainwright 4th Annual NASH Investor ConferenceMonday, October 5, 2020 3:30 pm ET

-- Guggenheim Securities 1st Annual Vaccines & Infectious Diseases DayMonday, October 5, 2020 4:45 pm ET

The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events/Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Companys diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visitwww.altimmune.com.

Investor Contacts

Stacey Jurchison Ashley R. RobinsonAltimmune, Investor Relations LifeSci Advisors, LLCPhone: 410-474-8200 617-430-7577sjurchison@altimmune.com arr@lifesciadvisors.com